Breaking News
September 26, 2018 - New insights into what drives organ transplant rejection
September 26, 2018 - Tiny Device Is a ‘Huge Advance’ for Treatment of Severe Heart Failure
September 26, 2018 - Research shows possibility to postpone cumbersome treatment for low-risk MDS patients
September 26, 2018 - CSU chemists may help in making extracorporeal life support devices more effective
September 26, 2018 - Blood-brain barrier can be important biomarker for early diagnosis of Alzheimer’s disease
September 26, 2018 - PCORI, AHRQ announce awards to support patient-centered outcomes research in learning health systems
September 26, 2018 - Scientists discover and characterize human skeletal stem cells
September 26, 2018 - Repeat CT Common in Peds Traumatic Epidural Hematoma
September 26, 2018 - Genetics Home Reference: bunion
September 26, 2018 - Increase observed in hearts from drug-intoxicated donors
September 26, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 26, 2018 - TINY cancer detection device shows promise as point-of-care detector of KSHV
September 26, 2018 - Women with non-small cell lung cancers live longer than their male counterparts
September 26, 2018 - KTU researchers engineer experimental bone to help treat osteoarthritis patients
September 26, 2018 - Foundation for a Smoke-Free World calls for proposals to implement Smoke-Free Index
September 26, 2018 - Functional Imagery Training helps lose five times more weight than talking therapy
September 26, 2018 - Fewer American Teens Having Sex, Most Using Birth Control
September 26, 2018 - We are predisposed to forgive, new research suggests
September 26, 2018 - Insomnia Exacts Heavy Toll on Quality of Life
September 26, 2018 - Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility
September 26, 2018 - Cytox, AIBL announce expanded agreement to assess genetic risk for Alzheimer’s
September 26, 2018 - Study finds persistent rate of lawnmower injury-related emergency department visits
September 26, 2018 - Researchers find molecule that halts, reverts neurodegeneration caused by Parkinson’s disease
September 26, 2018 - Novartis announces winners of 2018 eXcellence in Ophthalmology Vision Award
September 26, 2018 - New spinout company to tackle drug-resistant infections with novel antibiotics
September 26, 2018 - In depression the brain region for stress control is larger
September 26, 2018 - Smuggling RNA into cells can activate the immune system to fight cancer
September 26, 2018 - Special Focus Issue takes wide view of complementary and integrative medicine in cancer
September 26, 2018 - Researchers now confirm that genome duplication drives evolution of species
September 25, 2018 - Study provides evidence of beta lactamase producing, antimicrobial resistant E. coli in U.S. retail meat
September 25, 2018 - UCI study finds new cause of cerebral microbleeds
September 25, 2018 - Researchers propose mechanism by which ASTN2 protein defects lead to brain disorders
September 25, 2018 - Chinese and German researchers to cooperate more closely in future for better food
September 25, 2018 - Recent study helps predict probability of pregnant mothers to have child with autism
September 25, 2018 - New online, sound matching tool offers tinnitus sufferers potential treatment options
September 25, 2018 - UC Davis researchers take critical step in developing more effective Salmonella vaccine
September 25, 2018 - Antibiotics best paediatric treatment for children’s chronic wet cough
September 25, 2018 - Looking beyond opioids: Stanford pain psychologist briefs Congress
September 25, 2018 - Organs actively fighting back against autoimmune diseases, finds study
September 25, 2018 - Lancaster professor aims to understand how genes affect smoking cessation
September 25, 2018 - Human-oriented perspective needed to better understand Parkinson’s disease
September 25, 2018 - Physical activity may have beneficial effects for people with rare Alzheimer’s disease
September 25, 2018 - FDA Updates on Valsartan Recalls
September 25, 2018 - 3-D-printed tracheal splints used in groundbreaking pediatric surgery
September 25, 2018 - Who is the designated driver, or proxy, for your health decisions?
September 25, 2018 - New chemo-optogenetic method enables multi-directional activity control of cellular processes
September 25, 2018 - Study explores link between genetic predisposition to Alzheimer’s and cardiometabolic risk factors
September 25, 2018 - NeoTract presents new clinical data from studies of UroLift System for patients with BPH
September 25, 2018 - Patients with paralysis manage to walk thanks to new technology
September 25, 2018 - Statins Improve Long-Term Survival After AAA Repair
September 25, 2018 - Novel brain network linked to chronic pain in Parkinson’s disease
September 25, 2018 - Researchers reassess negative pressure wound therapy as its benefit and harm remain unclear
September 25, 2018 - Older adults with ‘fall plan of care’ less likely to suffer fall-related hospitalizations
September 25, 2018 - FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials
September 25, 2018 - IME Medical Electrospinning establishes state-of-the-art manufacturing lab facilities
September 25, 2018 - Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results
September 25, 2018 - How to Protect Your Eyesight
September 25, 2018 - Novel approach allows researchers to define how cells in the retina respond to diabetes
September 25, 2018 - Columbia University announces winners of 2018 Louisa Gross Horwitz Prize
September 25, 2018 - New model enables anyone to run powerful simulations, complex calculations easily
September 25, 2018 - Clinical trial investigators found non-compliant with requirement to report results on EU register
September 25, 2018 - Study analyzes quality of protein supplements in function of source, treatment and storage
September 25, 2018 - FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome
September 25, 2018 - U.S. Alzheimer’s Cases to Nearly Triple by 2060
September 25, 2018 - Improving cell replacement therapy for Parkinson’s disease
September 25, 2018 - Genervon reports new findings that drug candidate GM6 attenuates Alzheimer’s disease in mice model
September 25, 2018 - FDA approves new 5 mm diameter drug-eluting stent from Cook Medical
September 25, 2018 - New $17.8 million grant ensures USC at forefront of research on tobacco-related health risks
September 25, 2018 - Researchers analyze response to combination immunotherapy for patients with rare skin cancer
September 25, 2018 - Study sheds light on how brain protein may be involved neurodevelopmental disorders
September 25, 2018 - Where to draw the line on incentives
September 25, 2018 - Solid fuel use linked with increased risk of hospitalization or death from respiratory diseases
September 25, 2018 - ‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms
September 25, 2018 - Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE
September 25, 2018 - Global leaders must make bold commitments at first-ever UN tuberculosis summit
September 25, 2018 - Brief sleep intervention works long-term to prevent child obesity
September 25, 2018 - Vaping among kids and teens a growing concern
September 25, 2018 - Public launch of products and application solutions from Porvair Laboratory Division
September 25, 2018 - Harmful H. pylori may play a role in Parkinson’s disease
September 25, 2018 - Researchers develop way to measure different types of fear of falling in patients with Parkinson’s
Digital Pathology for Everyone

Digital Pathology for Everyone

image_pdfDownload PDFimage_print

An interview with Dr Martin Groher conducted by Alina Shrourou, BSc

Please give an overview of digital pathology today, and how pathologists currently share histology images to discuss diagnoses and further their studies.

There are two problems that pathologists face today. The first is, that a pathologist’s diagnosis using tissue sections is becoming more complex. There are many more biomarkers, and clinicians now ask for a more precise diagnosis. Secondly, the number of pathologists worldwide is declining every day, as the profession is often overlooked in favor of other specializations.

There is an opportunity for digital pathology to help solve these problems through telepathology. This is where workloads can be distributed remotely, and you can better respond to high work peaks.

Furthermore, digital pathology enables image analysis, which can optimize tasks during the diagnostic process for the pathologist and significantly speed up the diagnosis. Experts believe that every pathology lab needs to switch to digital pathology in the next three to five years to stay competitive.

How do the current digital pathology systems produce barriers, especially in smaller labs?

Digital pathology usually comes at high costs and effort, so you will have to invest quite significantly to get your lab to produce digital pathology outcomes. Currently, full-fledged digital pathology solutions cost around 0.5 to 1.5 million US dollars.

You will need a virtual slide scanner, storage systems, software for workflow management etc. Then, you must train all your employees which requires more costs. So, in the beginning, this solution is not cheap and takes quite some years to amortize. Unfortunately, many small labs cannot afford this.

Today, there are only few labs in the world that have gone completely digital. Some countries, like the Netherlands, or Scandinavian countries, are advanced in this area; but, for instance in Germany, or in the US, the transition to digital pathology in the clinical field is really slow.

With hardly any sources to get informed and without low-cost solutions to get started slowly, labs have a hard time anticipating or experiencing the benefits of digital pathology. This is the main barrier.

What methods are there for pathologists to share and discuss histology images?  What advantages does collaborating online bring to them?

Until the middle of 2017, there was no dedicated low-cost solution available for sharing and discussing histology images. Pathologists therefore turned toward ‘off the shelf’ tools like email, WhatsApp, Dropbox, or other file sharing systems, to send their image data to colleagues for case discussion. They even use social media networks such as Twitter and Facebook.

Pathologists are taking a risk by sharing health information via these unspecific communication channels, but they do this because there are significant advantages.

First of all, pathologists do not have to send the tissue or section by post to get a second opinion. Physical sending not only takes a long time but also bears the risk of loss – in the case of the glass slide you may even lose the evidence on which the diagnosis was made.

Digitizing pathology findings and sharing images online also provides better freedom to include a wider range of partners to discuss results. The pathologist can choose an expert (or several) with a high degree of specialism anywhere in the world to discuss his or her results with, rather than being limited to the local area.

One further advantage is that the pathologist could directly engage with patients, if needed. Image sharing was not designed for pathologists to talk to patients, but in a world where everyone can get informed through the internet, patients will often want to double-check their diagnosis with their pathologist to understand.

Therefore, these tools for online sharing and discussion give the opportunity to engage with other pathologists and patients, too.

Do the patients who have their images shared remain anonymous?

The pathologist must make sure that everything is de-identified and properly anonymized when sharing images – this is true for any image used in medical publication and on image sharing platforms. But of course, humans do make mistakes.

This brings us back to the point that there is a need for a dedicated solution – to take care of all of this and to avoid the sharing of protected health information through unprotected channels.

How easy or difficult is it for pathologists outside of large labs and research centers or those in remote regions, to access, share and discuss pathology images?

Small or mid-sized labs do usually not have access to any digital pathology solutions. They work on microscopes that will be equipped with digital cameras, or they will take photos through the ocular with their smart phones.

However, sharing and discussion is challenging, because free or low-cost communication channels are not there, or they are not safe. Therefore, it is definitely more difficult for pathologists outside of large labs to access, share and discuss pathology images.

The access to high quality image data, especially for those pathologists who are working in less developed countries and do not have advanced equipment, is also limited. Very often, digital pathology systems in large labs are incompatible for remote use.

This is because they are usually missing easy to access components to view and collaborate on data remotely, and the partnering lab would have to invest into software and integrate it, too.

There are a couple of web platforms which host high quality images, and make these available for the public, or for user restricted groups. These web platforms are focused on educational purposes and are often homemade by university hospitals or large institutions – and many lack the large variety that is out there for pathology images.

Please outline the new cloud-based image sharing platform that microDimensions has developed? What was the motivation and vision?

This is really where we step in with Anyslide. Here, our goal is to empower pathologists to benefit from digital pathology, no matter how advanced they are, or their lab is, on the digital journey. We want to compile and provide access to the largest variety of digital pathology data from any region and at the same time enable online collaboration on images – publicly or privately, and always securely.       

Anyslide is also very easy and intuitive to use, and of course, by providing a free, browser-based platform we eliminate the need for a pathologist to first ask for budget and then ask IT staff to get started.

The crucial information for all the pathologists and the pathology diagnosis lies in the images. Anyslide provides the easiest access to this information: via an image-hosting platform including tools for case discussion, sharing, and management.

How is the Anyslide platform unique compared to other existing platforms?

Anyslide is driven by digital pathology professionals and dedicated to pathologists.

Firstly, the platform is fully web and browser based. You can use it without any installation or expensive set up. The main difference is that it’s dedicated to pathologists, not for pathology labs.

This means that we avoid the costly effort to integrate with legacy systems, like laboratory information systems. By saving this effort and maintenance we cut down costs and are able to provide the first professional digital pathology platform entirely free of charge.

It is also different to “home-made” image collaboration platforms established by individuals, universities or other organizations. Anyslide provides an intuitive and user-proven interface as well as professional maintenance.

Finally, it is different to solutions from digital pathology hardware vendors, as it is truly neutral to the underlying imaging method – no matter if a lab has a high-end virtual slide scanner (from any vendor), a camera mounted on a microscope, or simply some smartphone snapshots through the ocular, Anyslide supports image-based collaboration.

What type of images and information can be shared on the platform? Are you able to search through the database for specific tissue types or conditions?

Anyslide users can share digital images created on their existing set-up. These include static images like jpeg, tiff or png (as taken by live capturing from microscope cameras) as well as whole slide images (WSI). This approach opens up digital pathology to a much larger group of pathologists than ever before.

Anyslide sets no limits to the information images are attributed with. Users can add tissue types, staining, condition, or diagnosis to their uploads. We clearly encourage and foster this diversity. The database can be searched by keywords and tags (#-based search) and a case-based organization of images is one of our next immediate steps for new functionality.

In the future, Anyslide may also offer methods for image analysis, to e.g. automatically tag them or compute a diagnostic score.

What happens if pathologists upload something with an incorrect diagnosis? Is there a proof-checking system in place?

This is something which is very important. We validate everything in a double, or triple fashion – by letting the crowd vote. When a new image is uploaded, pathologists on system that work within the expertise relevant to the recently uploaded image, will be asked if they agree with the diagnosis, set staining etc. Then with that, we create a vote and we can tell whether it’s correct, or not.

Who can access and use Anyslide? Is the platform open access or is there a cost attached to using the tool?

Everyone can access Anyslide. You can put your images online and share them publicly, and then you can view them, whether you’re a user of Anyslide or not. All you need is the link!

Of course, in order to edit, annotate, and describe your images, you need to have an account because we want to avoid an anonymous person annotating images. Account registration is free of charge.

For each image that you upload, you can choose to restrict it from the access of others, and just share it with a certain group of people for case discussions, for example; or you can also share it with the public for educational purposes.

You can also post a public image or a snapshot of an area of interest directly on your Twitter account from within Anyslide – for Whole Slide Images (WSI) this holds the possibility that your Twitter followers can follow back to the platform and to view it in its entirety and detail, add annotations, comments and questions.

Sign-up and the use of Anyslide is, and will stay, free of charge. We offer a professional subscription plan for those users that upload images exceeding a certain storage limit (currently, this is 5 GB per user). This small monthly fee will cover the larger storage costs.

What limitations are there to the Anyslide platform?

We launched Anyslide just two months ago, at the beginning of September 2017. That means that the platform is very young and the potential for future functionality and use cases is immense.

The nice thing is that it’s an opportunity for pathologists to get involved early and give us feedback. At this starting stage we are both eager and able to process feedback on user experience and new use cases and functionality.

What do you think the future holds for histology image collaboration through sharing platforms such as Anyslide in the healthcare and the pharma industry?

We want Anyslide to become the hub for pathology experts of all sub specialties worldwide. This should also include possibilities for every pathologist to offer their expertise to contractors from pharma or healthcare industries.

Currently, everyone is talking about how automation, computational analysis and artificial intelligence (AI) can revolutionize outcomes in the medical and pharma domain.

The problem that AI algorithms have is that they need a very large training and testing data base to be able to produce correct results. With the vision to become the world’s largest database of curated (=labeled) pathology image data, Anyslide will help to provide these rich data sets to companies working on better decision algorithms for oncology, for instance, or any other field of pathology.

Where can readers find more information?

Further information can be found on Anyslide.com

About Dr. Martin Groher

Dr. Martin Groher is CEO and co-founder of microDimensions, and he is responsible for strategy, sales, marketing, innovation and change management.

He received his PhD degree in Computer Science at the Chair for Computer Aided Medical Procedures, Department of Informatics at the Technical University of Munich.

After this, he led a group of scientists at the Technical University of Munich to work on histology reconstruction, where the original idea to microDimensions was born.

His visionary thinking combined with his deep knowledge of the digital pathology market and his profound expertise in image processing and analysis guarantee the continuous success of microDimensions’ products and services.

Tagged with:

About author

Related Articles